Apimeds Pharmaceuticals

Apimeds Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the development of bee venom-based therapeutics, a field known as apitherapy. The company's lead candidate, Apitox (purified bee venom), is being developed for the treatment of inflammatory and autoimmune conditions, including osteoarthritis and multiple sclerosis. Apitox has received marketing approval in South Korea and has undergone Phase 3 clinical trials in the United States for osteoarthritis. Apimeds leverages proprietary purification technologies to isolate active components from honeybee venom to create standardized, injectable treatments. The company is a subsidiary of the South Korean firm Inscobee and maintains operations in both South Korea and the United States.